Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Med Chem ; 17(5): 485-492, 2021.
Article in English | MEDLINE | ID: mdl-31702530

ABSTRACT

BACKGROUND: For more than 60 years, the lack of new anti-tuberculosis drugs and the increase of resistant Mycobacterium tuberculosis lineages exhibit a therapeutic challenge, demanding new options for the treatment of resistant tuberculosis. OBJECTIVE: Herein, we determined the (i) activities of (-)-camphene and its derivatives and (ii) combinatory effect with pyrazinamide (PZA) against Mycobacterium tuberculosis in acidic pH and (iii) cytotoxicity on VERO cells. METHODS: The activity of (-)-camphene and its 15 derivatives was determined in M. tuberculosis H37Rv in culture medium at pH 6.0 by Resazurin Microtiter Assay Plate (REMA). The activity and combinatory study of three (-)-camphene derivatives with PZA was carried out on seven multidrugresistant (MDR) clinical isolates by REMA and Checkerboard, respectively. The assay of 3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyltetrazolium (MTT) bromide in VERO cells was used to determine the derivatives' cytotoxicity. RESULTS: Four (-)-camphene derivatives, (4), (5a) (5d) and (5h), showed a reduction in the MIC value at pH 6.0 compared to the MIC detected at pH 6.8 in M. tuberculosis H37Rv and multidrug resistant clinical isolates. Three (-)-camphene derivatives, (4), (5d) and (5h), showed synergistic effect (FICI ≤ 0.5) combined with PZA and were more selective for M. tuberculosis than VERO cell (selective index from 7.7 to 84.2). CONCLUSION: Three (-)-camphene derivatives have shown to be promising anti-TB molecule scaffolds due to their low MIC values in acidic pH against MDR M. tuberculosis clinical isolates, synergism with PZA and low cytotoxicity.


Subject(s)
Antitubercular Agents/pharmacology , Bicyclic Monoterpenes/pharmacology , Mycobacterium tuberculosis/drug effects , Animals , Antitubercular Agents/chemistry , Antitubercular Agents/toxicity , Bicyclic Monoterpenes/chemistry , Bicyclic Monoterpenes/toxicity , Chlorocebus aethiops , Hydrogen-Ion Concentration , Microbial Sensitivity Tests , Stereoisomerism , Vero Cells
2.
Tuberculosis (Edinb) ; 110: 68-78, 2018 05.
Article in English | MEDLINE | ID: mdl-29779776

ABSTRACT

The high tuberculosis (TB) incidence rates, the closeness of the cities and the high migration flux on the Brazil/Paraguay/Argentina border deserves an in-depth study, using Mycobacterial Interspersed Repetitive Unit (MIRU) and Spoligotyping genetic markers to explore the impact of the Mycobacterium tuberculosis RDRio lineage on disease transmission and resistance to anti-TB drugs in this setting. Although without the totality of M. tuberculosis isolates causing TB in this studied setting, a number of 97 isolates obtained from sputa samples culture of patients with confirmed TB, from 2013 to 2015, were submitted to 24 loci MIRU, Spoligotyping, detection of RDRio lineage and detection of mutation related to isoniazid and rifampicin resistance by MTBDRplus/DNA STRIP. In this sample, it was observed high clonal variability of circulating M. tuberculosis isolates causing TB in Brazilian cities bordering Paraguay and Argentina. The percentage of RDRio lineage causing TB in this setting was 15.46%, and lower than the detected in different areas of Brazil. According to 24 loci MIRU, the major MIRU International Type (MIT) related with RDRio lineage were MIT 26, MIT 738, MIT 601 with four, two and one isolates, respectively. Eight isolates with RDRio marker were classified as orphans. The mainly Spoligofamily related with RDRio lineage was LAM1 and LAM9 and no relationship between RDRio lineage and resistance in M. tuberculosis isolates circulating in this setting could be established. This work is pioneer in studying the dynamics of RDRio lineage transmission on the Brazil/Paraguay/Argentina border and deserves further studies to analyze the real contribution of the RDRio lineage in outbreaks and the risk of significant development of MDR-TB in the setting studied.


Subject(s)
Mycobacterium tuberculosis/genetics , Tuberculosis/microbiology , Argentina/epidemiology , Bacterial Typing Techniques/methods , Brazil/epidemiology , Drug Resistance, Multiple, Bacterial/genetics , Genes, Bacterial , Genetic Markers , Humans , Incidence , Microbial Sensitivity Tests/methods , Mutation , Mycobacterium tuberculosis/classification , Mycobacterium tuberculosis/drug effects , Mycobacterium tuberculosis/isolation & purification , Paraguay/epidemiology , Tuberculosis/epidemiology , Tuberculosis/transmission
3.
Obstet Gynecol Surv ; 73(4): 219-230, 2018 Apr.
Article in English | MEDLINE | ID: mdl-29701867

ABSTRACT

IMPORTANCE: Hypothyroidism is one of the most prevalent diseases in pregnancy, but there is no consensus about its management in pregnant women. OBJECTIVE: In this systematic review, we evaluated the association between pregnancy complications and treated or untreated maternal hypothyroidism. EVIDENCE ACQUISITION: PubMed and reference lists were searched for the Medical Subject Headings terms "pregnancy complications" and "hypothyroidism." The eligibility criteria for inclusion in the study were an original study published between 2002 and 2013. Six reviewers independently selected the studies, and 3 extracted the data. Two reviewers assessed the risk of bias and quality of the studies. RESULTS: Eighteen studies were included in the systematic review. The most prevalent complications associated with maternal hypothyroidism were abortion, intrauterine fetal death, preterm delivery, and preeclampsia. The pregnancy outcome depended on the treatment that was received by the patient. CONCLUSIONS: Strong evidence indicates that maternal hypothyroidism is associated with maternal-fetal complications, but no consensus was found among the studies reviewed herein. The dose of levothyroxine that is required to maintain euthyroidism is still questioned, but studies have suggested that levothyroxine should be adjusted according to the gestational period and laboratory profile.


Subject(s)
Hypothyroidism/drug therapy , Pregnancy Complications/drug therapy , Thyroxine/adverse effects , Abortion, Spontaneous , Female , Fetal Death , Humans , Infant, Newborn , Maternal-Fetal Exchange , Pre-Eclampsia , Pregnancy , Pregnancy Outcome , Premature Birth , Thyroxine/administration & dosage
4.
J Reprod Immunol ; 123: 78-87, 2017 09.
Article in English | MEDLINE | ID: mdl-28985591

ABSTRACT

Antiphospholipid syndrome (APS) is an autoimmune condition that is associated with thrombosis and morbidity in pregnancy. The exact mechanisms by which these associations occur appear to be heterogeneous and are not yet well understood. The aim of this study was to identify and analyze publications in recent years to better understand the diagnosis and its contribution to monitoring APS among women with recurrent miscarriage (RM). This systematic review and meta-analysis was conducted using the PubMed and Web of Knowledge databases, with articles published between 2010 and 2014, according to the PRISMA statement. Of the 85 identified studies, nine were selected. Most of the studies reported an association between recurrent miscarriage and specific antiphospholipid antibodies, as anticardiolipin antibodies (aCL), lupus anticoagulant (LA), anti-ß2-glycoprotein I antibodies (aß2GPI) and antiphosphatidylserine (aPS), which showed a relationship with RM. The main result of the meta-analysis revealed association between antiphospholipid antibodies (aPLs) and/or APS compared to the patients with RM (OR: 0.279; 95% CI: 0.212-0.366) and APS cases compared to the patients with RM (OR: 0.083; 95% CI: 0.036-0.189). High heterogeneity among these studies (I2=100.0%, p <0.001) was observed. In addition, there was no significant publication bias across studies according to Begg's test (p=0.230), although Egger's test (p=0.037) suggests significant publication bias. The funnel plot was slightly asymmetrical. Systematic review and meta-analysis demonstrated a positive association between antiphospholipid antibodies and/or antiphospholipid syndrome in patients with recurrent miscarriage.


Subject(s)
Abortion, Habitual/diagnosis , Antibodies, Antiphospholipid/analysis , Antiphospholipid Syndrome/diagnosis , Lupus Erythematosus, Systemic/diagnosis , Adult , Antibodies, Anticardiolipin/analysis , Female , Humans , Lupus Coagulation Inhibitor/analysis , Monitoring, Physiologic , Phosphatidylserines/immunology , Pregnancy , Publication Bias , Reference Standards
SELECTION OF CITATIONS
SEARCH DETAIL
...